• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Concord Share Price

    Concord Drugs Share PriceConcord Drugs

    Small Cap 2.2k Result
    ₹35.94
    0.62 (1.76%)
    As on 06 December, 2023 | 15:40 BSE: 538965 NSE: CONCORDISIN: INE858L01010

    Concord Drugs Performance

    Day Range

    • Low
    • High
    ₹ 35.94

    52 Week Range

    • Low
    • High
    ₹ 35.94
    • Open Price
    • Previous Close
    • Volume

    Start SIP in Concord Drugs

    Start SIP

    Concord Drugs Share Price

    • Over 1 Month 9.04%
    • Over 3 Month -1.05%
    • Over 6 Month 30.69%
    • Over 1 Year 5.86%

    Concord Drugs Key Statistics

    Concord Drugs Investment Rating

    • Master Rating:

    • Concord Biotech Ltd has an operating revenue of Rs. 910.76 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 38% is great, ROE of 18% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 19% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Concord Drugs Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 791214141315
    Operating Expenses Qtr Cr 671112131215
    Operating Profit Qtr Cr 2111111
    Depreciation Qtr Cr 0000100
    Interest Qtr Cr 0000000
    Tax Qtr Cr 0000000
    Net Profit Qtr Cr 1000000
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 5159
    Operating Expenses Annual Cr 4753
    Operating Profit Annual in Cr 46
    Depreciation Cr 22
    Interest Annual Cr 22
    Tax Annual Cr 01
    Net Profit Annual Cr 12
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 21
    Cash from Investing Activity Annual Cr -20
    Cash from Financing Annual Activity Cr 02
    Net Cash Flow Annual Cr 02
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 3228
    Fixed Assets Annual Cr 1415
    Total Non Current Assets Annual Cr 1532
    Total Current Assets Annual Cr 4124
    Total Assets Annual Cr 5756
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 3432
    ROE Annual % 36
    ROCE Annual % 812
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 810
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 891413
    Operating Expenses Qtr Cr 681312
    Operating Profit Qtr Cr 2111
    Depreciation Qtr Cr 0010
    Interest Qtr Cr 0000
    Tax Qtr Cr 0000
    Net Profit Qtr Cr 1000
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Concord Drugs

    Concord Drugs Technicals

    EMA & SMA

    Current Price
    ₹35.94
    0.62 (1.76%)
    • Bullish Moving Average
    • ___
    • 0
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹34.51
    • 50 Day
    • ₹34.21
    • 100 Day
    • ₹33.44
    • 200 Day
    • ₹32.28
    • 20 Day
    • ₹34.31
    • 50 Day
    • ₹34.14
    • 100 Day
    • ₹33.78
    • 200 Day
    • ₹31.12

    Concord Drugs Resistance and Support

    PIVOT
    ₹35.28
    Resistance
    First Resistance 36.55
    Second Resistance 37.77
    Third Resistance 39.05
    RSI 55.64
    MFI 50.76
    MACD Single Line 0.17
    MACD 0.29
    Support
    First Resistance 34.05
    Second Resistance 32.77
    Third Resistance 31.55

    Concord Drugs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 21,614 1,252,747 57.96
    Week 16,132 1,097,446 68.03
    1 Month 14,032 1,030,243 73.42
    6 Month 18,910 1,250,929 66.15

    Concord Drugs Result Highlights

    Concord Drugs Synopsis

    NSE-Medical-Biomed/Biotech

    Concord Biotech Ltd. is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.17 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2023. Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ1984PLC007440 and registration number is 007440.
    Market Cap 14,031
    Sales 1,310
    Shares in Float 5.86
    No of funds 60
    Yield
    Book Value 10.97
    U/D Vol ratio 1.7
    LTDebt / Equity 3
    Alpha 0.41
    Beta 0.86

    Concord Drugs

    Owner NameSep-23
    Promoters 44.08%
    Mutual Funds 5.58%
    Insurance Companies 2.26%
    Foreign Portfolio Investors 7.3%
    Individual Investors 6.78%
    Others 34%

    Concord Drugs Management

    Name Designation
    Mr. Sudhir Vaid Chairman & Managing Director
    Mr. Ankur Vaid Joint Managing Director & CEO
    Mr. Ravi Kapoor Non Executive Director
    Mr. Rajiv Ambrish Agarwal Non Exe. & Nominee Director
    Mr. Utpal Sheth Non Exe. & Nominee Director
    Mr. Amit Varma Non Exe. & Nominee Director
    Ms. Bharti Khanna Independent Director
    Mr. Anil Katyal Independent Director
    Mr. Amitabh Thakore Independent Director
    Mr. Arvind Agarwal Independent Director
    Mr. Jayaram Easwaran Independent Director
    Mr. Mandayam Chakravarthy Sriraman Independent Director

    Concord Drugs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Concord Drugs Corporate Action

    Date Purpose Remarks
    2023-11-14 Quarterly Results
    2023-08-14 Quarterly Results
    2023-05-30 Audited Results
    2023-02-14 Quarterly Results
    2022-11-14 Quarterly Results

    Concord Drugs FAQs

    What is Share Price of Concord Drugs ?

    Concord Drugs share price is ₹35 As on 06 December, 2023 | 15:26

    What is the Market Cap of Concord Drugs ?

    The Market Cap of Concord Drugs is ₹33.5 Cr As on 06 December, 2023 | 15:26

    What is the P/E ratio of Concord Drugs ?

    The P/E ratio of Concord Drugs is 21.8 As on 06 December, 2023 | 15:26

    What is the PB ratio of Concord Drugs ?

    The PB ratio of Concord Drugs is 1.1 As on 06 December, 2023 | 15:26

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.